📋 Kidney and Liver: Two Major New Therapeutic Domains
The FLOW trial, Novo Nordisk's landmark study of semaglutide in patients with type 2 diabetes and chronic kidney disease, published its full results in the New England Journal of Medicine in May 2026 and showed that once-weekly semaglutide reduced the risk of the composite primary endpoint (kidney failure, doubling of serum creatinine, or death from kidney or cardiovascular causes) by 24% compared to placebo over a median follow-up of 3.4 years.
The trial enrolled 3,533 patients across 28 countries and was stopped early in October 2023 due to overwhelming efficacy at an interim analysis. Based on these results, the FDA approved an expansion of Ozempic's label to include reduction of kidney disease progression in December 2025.
Eli Lilly's SYNERGY-NASH Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, reported that 62% of patients receiving the highest dose of tirzepatide achieved MASH resolution without worsening of liver fibrosis at 52 weeks, compared to 14% on placebo. More importantly, 43% achieved at least one stage of fibrosis improvement without worsening of MASH, a dual endpoint that no therapy had previously met convincingly.
MASH affects approximately 115 million people globally and, before the GLP-1 era, had no approved therapies besides Madrigal Pharmaceuticals' resmetirom (Rezdiffra), approved in March 2024 as a thyroid hormone receptor-beta agonist.
❤️ Cardiovascular and Brain Effects
The SELECT cardiovascular outcomes trial, published in November 2023, showed that semaglutide reduced the risk of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) by 20% in overweight or obese patients with established cardiovascular disease but without diabetes, an indication for which Wegovy received FDA approval in March 2024. The mechanism appears to involve more than weight loss: the anti-inflammatory effects of GLP-1 agonism, including reductions in C-reactive protein, and direct effects on vascular endothelium and atherosclerotic plaque stability are now understood to contribute independently of metabolic improvements.
The most speculative and potentially transformative indication is neurodegenerative disease. The Phase 2 EVOKE trial of semaglutide in patients with early Alzheimer's disease reported at the 2026 American Academy of Neurology meeting a statistically significant but modest slowing of cognitive decline as measured by CDR-SB (Clinical Dementia Rating Sum of Boxes) of approximately 0.38 points over 18 months.
While this effect size is smaller than lecanemab's 0.45-point difference, the oral administration, favorable safety profile, and broad availability of GLP-1 drugs could make them an attractive option if confirmed in Phase 3 studies. Laboratory research has shown that GLP-1 agonists reduce neuroinflammation, improve synaptic plasticity, and decrease amyloid and tau pathology in animal models of Alzheimer's disease.
⚙️ Next-Generation Pipeline
The commercial scale of the GLP-1 market is staggering. Wegovy/Ozempic (semaglutide) and Mounjaro/Zepbound (tirzepatide) generated combined revenues of approximately $55 billion in the trailing twelve months through Q1 2026, making GLP-1 drugs the single largest drug class by revenue in pharmaceutical history. Production capacity has been the binding constraint: Novo Nordisk and Eli Lilly have invested $16 billion and $18 billion respectively in manufacturing expansion since 2023, and contract manufacturers including Catalent and Lonza have added substantial fill-finish capacity.
The first semaglutide biosimilars are expected in 2031 when compound and formulation patents begin to expire in major markets, though process patents extend further.
Next-generation candidates in the pipeline include oral small-molecule GLP-1 agonists from Eli Lilly (orforglipron, Phase 3), Pfizer (danuglipron, Phase 2 after earlier setback), and Structure Therapeutics, as well as multi-hormone receptor agonists such as retatrutide (GLP-1/GIP/glucagon triple agonist from Eli Lilly, Phase 3) that achieve weight loss exceeding 24% at 48 weeks. These newer agents aim to match or exceed the efficacy of injectable therapies while providing the convenience of oral dosing, further expanding the already vast population of eligible patients.